NMNerea Mora-Ayestarán

Nerea Mora-Ayestarán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nerea Mora-Ayestarán has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cumulative Genetic Burden Defines a Gradient of Risk in MYBPC3 -Related Hypertrophic Cardiomyopathy

    by Soledad García Hernandez, Luis De la Higuera Romero, Jose María Larrañaga-Moreira, Nerea Mora-Ayestaran, Maria Valverde-Gómez, Adrian Fernandez, Almudena Amor Salamanca, Maria Luisa Peña Peña, María Teresa Basurte-Elorz, Susana Martinez Huertas, et al.

    BACKGROUND: MYBPC3 truncating variants ( MYBPC3tv ) represent the most common genetic substrate in hypertrophic cardiomyopathy, yet carriers show substantial phenotypic variability despite a shared mechanism of haploinsufficiency. The contribution of additional genetic variants to this variability remains incompletely defined. METHODS: We analyzed 11 991 unrelated hypertrophic cardiomyopathy probands undergoing clinical genetic testing. Analyses focused on MYBPC3tv carriers stratified by additional intermediate-effect variants (IEVs) or second monogenic variants. IEVs were further classified as sarcomeric or nonsarcomeric. All probands were genetically characterized at a single center using standardized sequencing protocols, with uniform ascertainment of IEVs throughout the study period. Primary outcomes included age-related penetrance, maximal left ventricular wall thickness, and major adverse cardiovascular events; independent predictors were assessed by a multivariable Cox regression model. RESULTS: Among 2767 genotype-positive probands, MYBPC3 accounted for 47.6% of cases, with truncating variants representing 81.9% of MYBPC3 -positive individuals. Within MYBPC3tv carriers, additional variants were associated with a stepwise gradient of disease severity. Median age at diagnosis decreased from 48 years in isolated carriers to 42 years in MYBPC3tv +IEV and 28 years in double-monogenic carriers, whereas mean wall thickness increased from 21.3 to 24.1 and 26.3 mm, respectively. In multivariable analyses, cumulative genetic burden remained an independent predictor of major adverse cardiovascular event. Sarcomeric IEV carriers (hazard ratio, 10.3 [95% CI, 2.3–28.7]) and biallelic MYBPC3 carriers (hazard ratio, 23.2 [95% CI, 5.3–115.0]) exhibited the highest risk, although estimates in these subgroups should be interpreted cautiously given the limited number of events. All biallelic MYBPC3 carriers were diagnosed in childhood. CONCLUSIONS: Cumulative rare variant burden explains a subset of the phenotypic heterogeneity among MYBPC3tv carriers, defining a hierarchical gradient of disease expression. Intermediate-effect alleles and second monogenic variants, particularly biallelic MYBPC3 , identify higher-risk subgroups that may benefit from intensified surveillance, individualized management, and guided therapies.

  • Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy

    by Noemí Ramos-López, Nerea Mora-Ayestarán, Juan Pablo Ochoa, Eduard Claver, Cristina Gómez González, Edwin Poel, Mónica García Monsalvo, Guillem Casas, Carmen Muñoz-Esparza, María Teresa Basurte-Elorz, et al.

    BACKGROUND: Fibrosis assessed through late gadolinium enhancement (LGE) in cardiac magnetic resonance imaging and genetics have emerged as risk markers of ventricular arrhythmias in nonischemic dilated cardiomyopathy. Conduction corridors detected within LGE (ie, LGE corridors) have been associated with ventricular arrhythmias in ischemic cardiomyopathy. This study sought to evaluate major ventricular arrhythmic events (MVAs) according to the presence of LGE corridors combined with high-risk genotypes (HRGs) in nonischemic dilated cardiomyopathy. METHODS: We studied consecutive patients with nonischemic dilated cardiomyopathy from 22 European centers who had undergone genetic testing and cardiac magnetic resonance imaging. RESULTS: Among 925 patients (mean age, 54.5 years [interquartile range, 43.7–63.9 years]; 64% men; mean left ventricular ejection fraction, 37.6% [26.9%–44.8%]; LGE in 24.3%), LGE corridors were present in 160 patients (17.3%), and HRG in 119 (12.9%). After a median follow-up of 5.4 years (interquartile range, 3.3–7.7), 95 patients (10.3%) experienced an MVA. In multivariable competing-risk analysis adjusted for left ventricular ejection fraction and extent of LGE, the number of LGE corridors and HRGs were independently associated with MVA (subdistribution hazard ratio, 1.25 [95% CI, 1.11–1.42]; P P =0.003, respectively). An optimal cutoff of ≥4 LGE corridors predicted MVA. A stepwise risk stratification algorithm to predict MVA integrating LGE, the presence of ≥4 LGE corridors, and HRG outperformed left ventricular ejection fraction ≤35%–based classification proposed in guidelines (5-year time-dependent area under the curve, 0.72 [95% CI, 0.65–0.78] versus 0.57 [95% CI, 0.51–0.64]; P =0.001), showing a progressive increase in arrhythmic risk across categories (Gray test P <0.001), and allowing clinically meaningful arrhythmic risk classification. CONCLUSIONS: LGE corridors and HRGs provide additive value for arrhythmic risk stratification in patients with nonischemic dilated cardiomyopathy. These findings support MVA multiparametric prediction over the traditional left ventricular ejection fraction ≤35% threshold.

  • Adverse Remodeling and Fibrosis Predict Outcomes in Excessive Trabeculation of the Left Ventricle

    by Guillem Casas, Eduard Rodenas-Alesina, Javier Limeres, Garazi Urio-Garmendia, Albert Roque, Patricia Muñoz-Cabello, Jose M. Larrañaga-Moreira, Luigi Tassetti, Amudha Kumar, Tilman Emrich, et al.

  • Open Access

    Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy

    by Nerea Mora-Ayestarán, Noemi Ramos-Lopez, Juan Pablo Ochoa, Amaia Yuan Ibargoyen, Eduard Claver-Garrido, Cristina Gómez-González, Ahmad S. Amin, María Gallego-Delgado, Guillem Casas-Masnou, Marina Navarro-Peñalver, et al.

    BACKGROUND: Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study evaluated embolic risk in patients with dilated cardiomyopathy (DCM) according to the presence of hypertrabeculation and examined its prevalence and prognostic relevance across DCM genotypes. METHODS: Clinical data from 1160 patients with DCM evaluated by cardiac magnetic resonance imaging and genetic testing (n=997 [86%]) were collected from 22 international centers. End points included embolic events, advanced heart failure events, and major ventricular arrhythmias. RESULTS: LV hypertrabeculation was identified in 354 patients (30.5%) by fractal analysis and in 343 (29.7%) according to Petersen criteria, with good concordance. After a median follow-up of 5.1 years (interquartile range, 2.8–7.4), embolic events occurred in 37 patients (3.2%), advanced heart failure in 62 (5.3%), and major ventricular arrhythmias in 136 (11.7%). Hypertrabeculation was not associated with increased embolic risk (hazard ratio, 1.5 [95% CI, 0.75–3.00]), even among patients in sinus rhythm with LV ejection fraction ≤40% (hazard ratio, 1.89 [95% CI, 0.7–5.5]). In contrast, atrial fibrillation and reduced LV ejection fraction were associated with embolic events (both P TTN (38%), and genotype-negative status (33%), and the lowest prevalence observed among those with variants in cytoskeletal/Z-disk (7%) and nuclear envelope (5%) genes. Hypertrabeculation was not associated with adverse outcomes within any genotype. CONCLUSIONS: Although LV hypertrabeculation is common in DCM, it is not associated with worse outcomes and should not prompt differential clinical management. The embolic risk in patients with DCM and hypertrabeculation is low, including in those with reduced LV ejection fraction without atrial fibrillation, and does not support prophylactic anticoagulation in these patients.


  • Open Access

    Detection of Titin-Associated Electrocardiography Features in Dilated Cardiomyopathy Using Conventional and Deep Neural Network Analysis

    by Astrid B.M. Heymans, Rutger R. van de Leur, Ping Wang, Esther González-López, Max F.G.H.M. Venner, Nina J. Beelen, Steven A. Muller, Nerea Mora-Ayestarán, Noemi Ramos, Isa M.E. Faassen, et al.


  • Sex Differences in Prognosis of Patients With Genetic Dilated Cardiomyopathy

    by Sophie L.V.M. Stroeks, Marco Merlo, Nerea Mora-Ayestaran, Max Jason, Upasana Tayal, Ping Wang, Antonio Cannatà, Maurits A. Sikking, Matteo Dal Ferro, Belen Peiro, et al.

    BACKGROUND: Dilated cardiomyopathy (DCM) is a genetically heterogeneous disease, presenting diverse clinical phenotypes and outcomes based on the underlying gene affected. The influence of sex on the gene-specific long-term prognosis of patients with genetic DCM remains unclear. This study aims to determine the effect of sex on the long-term prognosis per underlying genogroup. METHODS: A retrospective cohort study was conducted using data from 4 international referral centers. Baseline and longitudinal clinical data of patients with DCM, with a median follow-up of 6.7 years (interquartile range, 3.5–11.9 years), were collected. The study included men and women with DCM who had undergone genetic testing. Patients were categorized into 7 genotype groups: cytoskeletal/Z-disk, desmosomal, nuclear envelope, motor sarcomeric, TTN , other genetic, and genotype negative. The main outcomes measured were left ventricular reverse remodeling, mortality, heart failure hospitalization, heart transplantation, and malignant ventricular arrhythmias. RESULTS: Among 1716 patients, 1130 (66%) were men and 510 (30%) had a (likely) pathogenic variant. Ventricular remodeling was gene-dependent in women, with TTN patients exhibiting the highest rate ( P =0.003) and desmosomal patients the lowest ( P =0.04) compared with the genotype-negative group. After a median follow-up of 6.7 years, 334 men (29%) and 140 women (24%) reached the primary end point. Men with a (likely) pathogenic variant had the poorest prognosis, showing a higher rate of major adverse events (adjusted hazard ratio, 1.48 [95% CI, 1.12–1.95]; P =0.02) and malignant ventricular arrhythmias (adjusted hazard ratio, 1.83 [95% CI, 1.16–2.88]; P =0.009) compared with genotype-negative women. Prognosis varied by gene in men (log-rank P P =0.1). The cytoskeletal/Z-disk, desmosomal, and nuclear envelope groups had the worst prognosis in men. CONCLUSIONS: The genetic architecture and sex are critical predictors of left ventricular reverse remodeling and long-term prognosis in DCM. These factors should be integrated into individualized risk prediction models to enhance clinical outcomes in patients with DCM.


  • Open Access

    Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants

    by Soledad García Hernandez, Luis de la Higuera Romero, Adrian Fernandez, Maria Luisa Peña Peña, Nerea Mora-Ayestaran, María Teresa Basurte-Elorz, Jose María Larrañaga-Moreira, Ivonne Cárdenas Reyes, Eduardo Villacorta, Maria Valverde-Gómez, et al.

    BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes, although recently certain nonsarcomeric genes have emerged as important contributors. Nonmendelian genetic variants with reproducible moderate-effect sizes and low penetrance, intermediate-effect variants (IEVs), can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel the complex genetic architecture of HCM. METHODS: We conducted an ancestry-based enrichment analysis of 14 validated HCM genes, including the 9 core sarcomeric and 5 nonsarcomeric genes (ALPK3 , CSRP3 , FHOD3 , FLNC , and TRIM63 ). Enrichment of intermediate frequency missense variants was evaluated in 10 981 patients with HCM, 4030 internal controls of European-ancestry, and 590 000 external controls from gnomAD non-Finnish Europeans. The population-attributable fraction was calculated to assess contribution of IEVs to HCM. Age-related disease penetrance, phenotypic severity (left ventricular maximum wall thickness), and major adverse cardiac events were analyzed in 11 991 HCM cases of the whole cohort according to 5 genetic groups: genotype negative, isolated IEV, monogenic, monogenic+IEV, and double monogenic. RESULTS: Fourteen IEVs in 8 genes were identified in 731 individuals (6.1% of the cohort), of whom 570 patients (4.8%) had IEVs in isolation: 198 (34.7%) in sarcomeric genes and 372 (65.3%) in nonsarcomeric genes. The contribution of IEVs to HCM genetics according to population-attributable fraction was estimated to be 4.9% (95% CI, 3.2–6.7). A significant gradient in penetrance, phenotypic severity, and major adverse cardiac events was observed across genetic groups. Compared with genotype-negative patients, IEV carriers displayed a younger median age at diagnosis (59 years of age [95% CI, 46–69] versus 61 years [95% CI, 49–70]; P =0.0073) and a higher mean left ventricular maximum wall thickness (18.1±3.7 versus 19.0±4.3; P =0.0043). IEVs also modified disease expression in individuals with monogenic variants, causing a more aggressive phenotype than in individuals from the monogenic-only group with HCM onset at younger age and a higher left ventricular maximum wall thickness (all P P <0.0001). CONCLUSIONS: IEVs are present in 6.1% of HCM cases and account for 4.8% of HCM genetic burden. IEVs also influence disease severity and outcomes, particularly when combined with monogenic disease-causing variants. Evaluation of IEVs should be considered when HCM genetic testing is performed.


  • Open Access

    Impact of Genetic Testing Family Screening in Hereditary Transthyretin Amyloidosis

    by Nerea Mora-Ayestarán, Celia Gil-Llopis, Clea González-Maniega, Maria Victoria Piovano, Daniel Águila-Gordo, Ana Briceño, Emiliano González-Vioque, Fernando Domínguez, Esther González-López, Pablo Garcia-Pavia


  • Electrophysiological Phenotype-Genotype Study of Sustained Monomorphic Ventricular Tachycardia in Inherited, High Arrhythmic Risk, Left Ventricular Cardiomyopathy

    by Eva Cabrera-Borrego, Francisco J. Bermúdez-Jiménez, Alessio Gasperetti, Harikrishna Tandri, Pablo J. Sánchez-Millán, Manuel Molina-Lerma, Ivo Roca-Luque, Sara Vázquez-Calvo, Paolo Compagnucci, Michela Casella, et al.

    BACKGROUND: Among inherited cardiomyopathies involving the left ventricle, whether dilated or not, certain genotypes carry a well-established arrhythmic risk, notably manifested as sustained monomorphic ventricular tachycardia (SMVT). Nonetheless, the precise localization and electrophysiological profile of this substrate remain undisclosed across different genotypes. METHODS: Patients diagnosed with cardiomyopathy and left ventricle involvement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruited from 18 European/US centers. Electrophysiological study, imaging, and outcomes data after ablation were assessed in relation to genotype. RESULTS: Seventy-one patients were included (49.6 Q1–Q3 [40–60] years, 76% men). They were divided into 4 groups according to the affected protein: desmosomal ( DSP , PKP2 , DSG2 , and DSC2 ), nuclear membrane ( LMNA and TMEM43 ), cytoskeleton ( FLNC and DES ), and sarcoplasmic reticulum ( PLN ). Desmosomal genes, TMEM43 , and PLN were associated with biventricular disease, while variants in LMNA and cytoskeleton genes had predominant left ventricle involvement ( P =0.001). The location of the clinical-SMVT substrate was significantly different based on genotype ( P =0.005). DSP and cytoskeleton genes presented SMVTs with right bundle branch block morphology, which origin was identified in the inferolateral segments of the left ventricle. The other desmosomal genes ( PKP2 and DSG2 ), along with TMEM43 , showed SMVTs with left bundle branch block morphology and predominantly right ventricular substrate. In contrast, LMNA substrate was mainly observed in the interventricular septum. During a median of 26 Q1–Q3 (10.6–65) months, 27% of patients experienced recurrences of clinical SMVT with differences between genotypes (log-rank 0.016). Nuclear membrane genes demonstrated the highest recurrence rate compared with desmosomal genes (hazard ratio, 4.56 [95% CI, 1.5–13.8]). CONCLUSIONS: The anatomic substrate of SMVTs shows a strong correlation with the underlying genotype, electrocardiographic morphology, and recurrence rate. Particularly, patients with nuclear membrane gene variants have a significantly higher recurrence rate compared with those with desmosomal gene variants.